Schonfeld Strategic Advisors’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-15,558
| Closed | -$159K | – | 2160 |
|
|
2025
Q1 | $159K | Buy |
+15,558
| New | +$159K | ﹤0.01% | 1839 |
|
|
2024
Q4 | – | Sell |
-199,354
| Closed | -$11.6M | – | 2098 |
|
|
2024
Q3 | $11.6M | Buy |
199,354
+165,241
| +484% | +$9.6M | 0.08% | 214 |
|
|
2024
Q2 | $1.56M | Sell |
34,113
-26,292
| -44% | -$1.2M | 0.01% | 891 |
|
|
2024
Q1 | $4M | Sell |
60,405
-34,933
| -37% | -$2.31M | 0.03% | 606 |
|
|
2023
Q4 | $3.79M | Buy |
95,338
+17,538
| +23% | +$697K | 0.03% | 538 |
|
|
2023
Q3 | $2.48M | Sell |
77,800
-8,927
| -10% | -$285K | 0.02% | 659 |
|
|
2023
Q2 | $3.48M | Buy |
86,727
+30,182
| +53% | +$1.21M | 0.03% | 588 |
|
|
2023
Q1 | $2.41M | Buy |
56,545
+16,245
| +40% | +$694K | 0.02% | 638 |
|
|
2022
Q4 | $1.94M | Buy |
+40,300
| New | +$1.94M | 0.02% | 832 |
|
|
2022
Q2 | – | Sell |
-18,097
| Closed | -$984K | – | 2675 |
|
|
2022
Q1 | $984K | Buy |
18,097
+2,053
| +13% | +$112K | 0.01% | 942 |
|
|
2021
Q4 | $939K | Buy |
+16,044
| New | +$939K | 0.01% | 912 |
|
|
2021
Q2 | – | Sell |
-17,046
| Closed | -$1.05M | – | 2073 |
|
|
2021
Q1 | $1.05M | Buy |
+17,046
| New | +$1.05M | 0.01% | 836 |
|